Effects of mosapride CITRATE (cas 13754-17-1), metoclopramide hydrochloride, lidocaine hydrochloride, and cisapride CITRATE (cas 13754-17-1) on equine gastric emptying, small intestinal and caecal motility
-
Add time:09/27/2019 Source:infona.pl
Although extensive work has been done to elucidate the beneficial and unfavorable effects of gastrointestinal prokinetic agents in humans, little is known on the effects of these agents in horses. In this study, we compared the effects of mosapride, metoclopramide, cisapride, and lidocaine on equine gastric emptying, jejunal and caecal motility and evaluated these agents’ adverse drug reactions (ADRs).Seven healthy adult Thoroughbreds.Mosapride 1.0mg/kg and 2.0mg/kg, metoclopramide 0.2mg/kg, and cisapride 1.0mg/kg were dissolved in 100mL distilled water for oral administration. Lidocaine 1.3mg/kg was mixed with 500mL saline for a 30-min intravenous infusion. Oral administration of 100mL distilled water was used as control. Gastric emptying was evaluated using 13 CO 2 breath test, and jejunal and caecal motility was assessed by electrointestinography.The present study demonstrates that mosapride at doses of 1.0mg/kg and 2.0mg/kg facilitates gastric emptying in horses. Improved jejunal motility was observed following administration of mosapride (1.0mg/kg and 2.0mg/kg), metoclopramide (0.2mg/kg), and cisapride (1.0mg/kg). Similarly, improved caecal motility was observed following administration of mosapride (2.0mg/kg).This study shows that among the prokinetic agents studied here, only mosapride (2.0mg/kg) promotes jejunal and caecal motility in horses. Considering mosapride ADRs profile, it is believed that this compound is useful in the treatment of diseases associated with decreased GI motility, including postoperative ileus.
We also recommend Trading Suppliers and Manufacturers of CITRATE (cas 13754-17-1). Pls Click Website Link as below: cas 13754-17-1 suppliers
Prev:A randomized controlled trial of the efficacy of rosiglitazone and clomiphene CITRATE (cas 13754-17-1) versus metformin and clomiphene CITRATE (cas 13754-17-1) in women with clomiphene CITRATE (cas 13754-17-1)–resistant polycystic ovary syndrome
Next:Combined pioglitazone–metformin and clomiphene CITRATE (cas 13754-17-1) versus metformin and clomiphene CITRATE (cas 13754-17-1) in induction of ovulation in women with clomiphene CITRATE (cas 13754-17-1)-resistant polycystic ovary syndrome) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Tributyl CITRATE (cas 13754-17-1) as an effective plasticizer for biodegradable polymers: effect of plasticizer on free volume and transport and mechanical properties09/30/2019
- Effect of trisodium CITRATE (cas 13754-17-1) on electrolytic deposition of hydroxyapatite coatings09/29/2019
- Structures of mesophilic and extremophilic CITRATE (cas 13754-17-1) synthases reveal rigidity and flexibility for function09/28/2019
- Combined pioglitazone–metformin and clomiphene CITRATE (cas 13754-17-1) versus metformin and clomiphene CITRATE (cas 13754-17-1) in induction of ovulation in women with clomiphene CITRATE (cas 13754-17-1)-resistant polycystic ovary syndrome10/01/2019
- A randomized controlled trial of the efficacy of rosiglitazone and clomiphene CITRATE (cas 13754-17-1) versus metformin and clomiphene CITRATE (cas 13754-17-1) in women with clomiphene CITRATE (cas 13754-17-1)–resistant polycystic ovary syndrome09/26/2019
- Observational Study of Need for Thrombolytic Therapy and Incidence of Bacteremia using Taurolidine‐CITRATE (cas 13754-17-1)‐Heparin, Taurolidine‐CITRATE (cas 13754-17-1) and Heparin Catheter Locks in Patients Treated with Hemodialysis09/25/2019